Title:
IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY
Document Type and Number:
WIPO Patent Application WO/2018/059549
Kind Code:
A1
Abstract:
Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
More Like This:
Inventors:
MOTZ GREGORY (US)
MAVRAKIAS KONSTANTINOS JOHN (US)
LIU JINBIAO (CN)
LIU LEI (CN)
ZHENG QIANGANG (CN)
XUN GUOLIANG (CN)
XIAO QITAO (CN)
MAVRAKIAS KONSTANTINOS JOHN (US)
LIU JINBIAO (CN)
LIU LEI (CN)
ZHENG QIANGANG (CN)
XUN GUOLIANG (CN)
XIAO QITAO (CN)
Application Number:
PCT/CN2017/104422
Publication Date:
April 05, 2018
Filing Date:
September 29, 2017
Export Citation:
Assignee:
NOVARTIS AG (CH)
UNIV PENNSYLVANIA (US)
MOTZ GREGORY (US)
MAVRAKIAS KONSTANTINOS JOHN (US)
LIU JINBIAO (CN)
LIU LEI (CN)
ZHENG QIANGANG (CN)
XUN GUOLIANG (CN)
XIAO QITAO (CN)
UNIV PENNSYLVANIA (US)
MOTZ GREGORY (US)
MAVRAKIAS KONSTANTINOS JOHN (US)
LIU JINBIAO (CN)
LIU LEI (CN)
ZHENG QIANGANG (CN)
XUN GUOLIANG (CN)
XIAO QITAO (CN)
International Classes:
C07D401/04; A61K31/33; A61P35/00; C07D209/14
Domestic Patent References:
WO2017149463A1 | 2017-09-08 | |||
WO2017114497A1 | 2017-07-06 | |||
WO2015134973A1 | 2015-09-11 | |||
WO2016029262A1 | 2016-03-03 | |||
WO2014205511A1 | 2014-12-31 | |||
WO2013033688A1 | 2013-03-07 | |||
WO2005044996A2 | 2005-05-19 | |||
WO2016014565A2 | 2016-01-28 |
Foreign References:
US20160152595A1 | 2016-06-02 |
Other References:
See also references of EP 3523290A4
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: